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Abstract Neuro¢bromin, a neuro¢bromatosis type I (NF1) tu-
mor suppressor gene product, has a domain acting as a GTPase
activating protein and functions in part as a negative regulator
of Ras. Loss of neuro¢bromin expression in NF1 patients is
associated with elevated Ras activity and increased cell prolif-
eration. Therefore, regulation of the function of neuro¢bromin is
heavily involved in cell growth and di¡erentiation. In the present
study, we identi¢ed a novel cellular neuro¢bromin-associating
protein, 14-3-3, which belongs to a highly conserved family of
proteins that regulate intracellular signal transduction events in
all eukaryotic cells. The interaction of 14-3-3 is mainly directed
to the C-terminal domain (CTD) of neuro¢bromin, and the
cAMP-dependent protein kinase (PKA)-dependent phosphoryla-
tion clustered on CTD-Ser (2576, 2578, 2580, 2813) and Thr
(2556) is required for the interaction. Interestingly, the in-
creased phosphorylation and association of 14-3-3 negatively
regulate the function of neuro¢bromin. These ¢ndings indicate
that PKA phosphorylation followed by 14-3-3 protein interac-
tion may modulate the biochemical and biological functions of
neuro¢bromin.
7 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Neuro¢bromatosis type I (NF1), or von Recklinghausen
neuro¢bromatosis, is one of the most common autosomal
dominantly inherited disorders, with an incidence of approx-
imately 1 in 3500 individuals [1], and is characterized by the
development of benign tumors of the peripheral nervous sys-
tem and increased risk of developing malignancies [2^5]. The
phenotype of NF1 is highly variable with several organ sys-
tems being a¡ected, including bones, skin, irises and central
nervous system, and manifests as neuro¢broma, gliomas and
learning disabilities [3]. The NF1 gene was identi¢ed by posi-
tional cloning and found to encode a large 250-kDa cytoplas-
mic protein product, neuro¢bromin. Sequence analysis of neu-
ro¢bromin revealed a region of homology with the Ras
GTPase activating protein (GAP) family, including vertebrate
p120-GAP, yeast ira1 and ira2, and Drosophila Gap1 [2]. Ras-
GAPs are considered to attenuate signaling from Ras, thus
blocking the transmission of signals leading to increased
growth or di¡erentiation [6].
Since the Ras-GAP domain of neuro¢bromin comprises
only 10% of the whole polypeptide, we speculated that other
regions of this protein are crucial for modulating cell growth
or other processes related to NF1-related disease. In Droso-
phila, homozygous null mutation of the NF1 gene causes a
reduction in body size, which is an obvious sign of perturbed
Ras-mediated signaling, and this phenotype can be rescued by
expression of activated cAMP-dependent protein kinase
(PKA) [7]. Neuro¢bromin and PKA thus appear to interact
in a pathway that controls the growth of Drosophila. Addi-
tionally, we previously reported that neuro¢bromin is consti-
tutively phosphorylated and that the speci¢c phosphorylation
lies on the cysteine/serine-rich domain (CSRD) and the C-ter-
minal domain (CTD) of neuro¢bromin [8]. In vitro and in gel
kinase assays suggest that PKA is a candidate for the neuro-
¢bromin kinase. All these observations led to the hypothesis
that some NF1-associated proteins, which are phosphoryla-
tion-dependent, may have regulatory e¡ects on the function
of neuro¢bromin. Searching for NF1-associated proteins is
therefore of particular interest as it may lead to the identi¢-
cation of novel cellular components that play important roles
in Ras regulation, and should also further our understanding
of the mechanism of NF1-related pathogenesis.
In a recent report, we sought to identify a cellular neuro-
¢bromin-interacting protein from a bovine brain cytosolic
fraction using a⁄nity column-immobilized CTD of neuro¢-
bromin, and characterized it as NG,NG-dimethylarginine di-
methylaminohydrolase (DDAH), which is known as a cellular
NO/NO synthase regulator [8]. DDAH increased PKA phos-
phorylation accessibility of neuro¢bromin via the CSRD and
CTD [8], suggesting that phosphorylation of neuro¢bromin is
regulated by its associating proteins and controls the cellular
function of neuro¢bromin.
In this study, we use the same approach and identify 14-3-3
as another CTD binding protein. PKA-mediated phosphory-
lation of neuro¢bromin promotes association with 14-3-3.
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Furthermore, we demonstrate that 14-3-3 association nega-
tively regulates NF1-GAP activity by using a newly developed
NF1-GAP assay method. These ¢ndings suggest that 14-3-3
modulates the biochemical and biological functions of neuro-
¢bromin through PKA-mediated phosphorylation.
2. Materials and methods
2.1. Preparation of glutathione S-transferase (GST) fusion proteins
We generated four GST-neuro¢bromin domain fusion proteins cor-
responding to sequences of residues 543^909, 1168^1530, 1545^1950,
and 2260^2818 of neuro¢bromin, which were designated CSRD,
GAP-related domain (GRD), leucine repeat domain (LRD), and
CTD, respectively [9]. GST-14-3-3R was produced by polymerase
chain reaction (PCR) ampli¢cation and cDNA cloning into the
pGEX-3X vector as described [10]. Expression and puri¢cation of
each GST fusion protein were performed according to our previously
described protocol [8].
2.2. Plasmid construction
The cDNA for myc-tagged 14-3-3R was generated by PCR ampli-
¢cation as described [10]. The PCR fragment was digested with MluI
and BamHI, and then inserted into the cloning site of myc tag vector
pMUM1. The myc-tagged 14-3-3R cDNA was then digested with
HindIII and XbaI, and inserted into the mammalian expression vector
pcDNA3 (Invitrogen) [10].
2.3. Antibodies
Antibodies against the C-terminus of neuro¢bromin [anti-GRP (D)]
and 14-3-3 were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The anti-myc-tag monoclonal antibody was pur-
chased from MBL (Nagoya, Japan). The anti-GST goat antibody
was purchased from Amersham. An anti-NF1-GAP antibody was
generated as previously described [11].
2.4. Preparation of cytosolic fraction from rat brain
Cytosolic fraction of rat brain was prepared as previously described
[8]. In brief, rat brain was homogenized with lysis bu¡er A (20 mM
Tris^HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2, 150 mM NaCl, and
0.1% NP-40), containing 1 mM 4-(2-aminoethyl)-benzenesulfonyl £u-
oride hydrochloride (p-ABSF), 20 Wg/ml aprotinin, 1.5 WM pepstatin
A, 10 Wg/ml leupeptin, and 500 WM Na3VO4 in a Dounce type ho-
mogenizer. The homogenized sample was centrifuged at 14 000 rpm
for 20 min, and the supernatant was used for the experiments. All
experiments described were performed at 4‡C or on ice.
2.5. Detection and identi¢cation of binding proteins from rat brain
cytosolic fraction by GST-CTD a⁄nity chromatography
GST-CTD fusion protein immobilized on GSH-agarose was packed
into a column and equilibrated with bu¡er B (30 mM Tris^HCl, pH
7.5, 1 mM EDTA, 5 mM MgCl2, and 1 mM dithiothreitol (DTT)).
Rat brain cytosolic fraction, pre-cleared by passing through a GSH
column, was then loaded onto the GST-CTD column. After washing
the column with bu¡er B, the proteins bound to the column were
eluted by the addition of bu¡er C (bu¡er A containing 0.5 M
NaCl), and subjected to sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE), followed by silver staining. For identi-
¢cation of the bound protein, the protein band detected in SDS^
PAGE was cut and sliced into small pieces. The gels were then de-
salted in 50% methanol and 100% acetonitrile, dried in a Speed-Vac,
and soaked again with digestion bu¡er containing trypsin. After over-
night protein digestion, the supernatant was again desalted by Zip tips
(Millipore Corporation, Bedford, MA, USA) and used for sequence
analysis by nano infusion ESI tandem mass spectrometry (Qstar pul-
sar i, Applied Biosystems Japan). The amino acid sequence obtained
from mass-¢t and product ion analysis was used to search for se-
quence similarity against the PIR International database and/or
SwissProt using MASCOT search engine. Alternatively, the proteins
separated with the SDS^PAGE were electroblotted onto a nitrocellu-
lose membrane, and then probed with the anti-14-3-3 antibodies.
After reaction with the horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies, the reacted protein bands on the membrane were
visualized by an ECL detection system (Amersham).
2.6. Cell culture and transfection
COS-7 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
nutrient mixture F-12 Ham (Sigma, St. Louis, MO, USA) with 10%
fetal bovine serum. To transiently express myc-14-3-3R, pcDNA3-
myc-14-3-3R was transfected into COS-7 cells with Fugene 6 (Roche)
according to the manufacturer’s protocol. PC12 cells were grown on
collagen-coated tissue culture plates in RPMI 1640 medium supple-
mented with 10% heat-inactivated horse serum and 5% fetal bovine
serum, as described previously [11]. PC12 cells permanently expressing
myc-14-3-3R (termed PC12 14-3-3R cells) were prepared as described
[10].
2.7. Immunoprecipitation assays
Immunoprecipitation was conducted on lysates of COS-7 or PC12
cells transfected with or without pcDNA3 myc-14-3-3R. Cells were
lysed with bu¡er A containing 1 mM p-ABSF, 5 Wg/ml aprotinin,
1 Wg/ml pepstatin A, 1 Wg/ml leupeptin, 10 mM NaF, 2 mM Na3VO4,
and 1 WM okadaic acid, and passed through a 25-G syringe 15 times.
The lysates were centrifuged at 14 000 rpm for 20 min at 4‡C, the
protein concentrations of the supernatant were determined using the
BCA protein assay reagent (Pierce). The lysates were normalized in
the same protein concentration, mixed with 4 Wg of anti-myc antibody
(MBL) or anti-neuro¢bromin [GRP (D)] (Santa Cruz) and protein G
plus/protein A agarose (Oncogene Science), and then rocked for 2 h at
4‡C. Immunoprecipitates were washed with bu¡er A and boiled in 30
Wl of 2USDS loading bu¡er. Samples were subjected to SDS^PAGE
and electro-transferred onto membranes, and then probed with anti-
myc or anti-neuro¢bromin [GRP (D)]. After reaction with the HRP-
conjugated secondary antibodies, the immunoreactive proteins on the
membrane were visualized by an ECL detection system (Amersham).
2.8. GST pull-down assay for the interaction of various GST fusion
fragments of neuro¢bromin
COS-7 cells were transfected with or without pcDNA3-myc-14-3-
3R, and lysed with cell lysis bu¡er as described above. The cell lysates
were incubated with GST alone or various GST-neuro¢bromin do-
main fusion proteins immobilized to GSH-agarose for 2 h at 4‡C. The
protein complexes with agarose beads were recovered by centrifuga-
tion, washed three times with cell lysis bu¡er, and subjected to SDS^
PAGE followed by immunoblotting analysis as described above.
2.9. Phosphorylation assay of GST-CTD by PKA
GST-CTD fusion protein (100 Wg) was incubated with 50 Wl of 50%
GSH-agarose in phosphate-bu¡ered saline (PBS) for 2 h at 4‡C. The
GST-CTD fusion protein immobilized on GSH-agarose was incuba-
ted with or without 30 U PKA (Sigma) in a total volume of 100 Wl
kinase assay bu¡er (20 mM Tris^HCl (pH 7.4), 10 mM MgCl2, 50
mM KCl, and 0.1 mM ATP) at 37‡C for 30 min. The reaction was
terminated by washing with cold PBS containing 0.1 mM DTT. Then
the immobilized protein was incubated with cell lysates of PC12 14-3-
3R in the presence or absence of 2 WM PKA-inhibitor peptide (PKI-
[6^22] amide, Sigma).
2.10. Assay for NF1-GAP activity
The GAP activity assay was performed as previously described [11].
In brief, cell lysates in the presence or absence of anti-NF1-GAP
antibody were incubated with GST-H-Ras preincubated with [Q-32P]-
GTP, and the sample was passed through a nitrocellulose ¢lter (0.45
Wm; Schleicher and Schuell). After washing, the radioactivity of the
¢lter was counted. Speci¢c NF1-GAP activity was obtained from the
di¡erence between the sample radioactivities after the reaction with
and without anti-NF1-GAP IgG. We also analyzed the binding e⁄-
ciency of NF1 protein to Ras-GTP for evaluating the GAP activity of
endogenous NF1 protein. To prepare the GTPQS- (or GDPLS-) bound
form of Ras, 200 Wg of GST-H-Ras was preincubated with 80 Wl of
50% GSH-agarose in PBS for 2 h at 4‡C in 200 Wl of GAP assay
bu¡er (0.25 M Tris^HCl, pH 8.0, 25 mM EDTA, 0.25 M MgCl2 and
0.25 M DTT), and washed twice with the same bu¡er, and then once
with GST loading bu¡er (20 mM Tris^HCl, pH 7.5, 5 mM MgCl2, 20
mM EDTA, 100 mM NaCl, 10% glycerol, and 2.5 mg/ml bovine
serum albumin). The GST-H-Ras beads were then incubated with
10 Wl of 10 mM GTPQS or GDPLS for 30 min at 37‡C, and washed
three times with bu¡er A. Cell lysates of PC12 or PC12 14-3-3R cells
were incubated with the GST-Ras-GTPQS or GST-Ras-GDPLS for 2 h
at 37‡C with rocking, and washed three times with bu¡er A. The
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bound form of cellular neuro¢bromin (active form) on the beads was
separated with the SDS^PAGE, electroblotted onto the membrane,
and detected with the anti-neuro¢bromin [GRP (D)] antibody, fol-
lowed by reaction with the HRP-conjugated secondary antibodies
and visualization by an ECL detection system (Amersham). To study
the e¡ect of PKA phosphorylation on GAP activity of cellular neuro-
¢bromin, 50 WM forskolin was used to treat PC12 14-3-3R cells for 20
min at 37‡C, and then the binding e⁄ciency of neuro¢bromin with
14-3-3R or with GST-H-Ras GTPQS was compared with that of cells
not treated with forskolin, as described above.
2.11. Site-directed mutagenesis of GST-CTD
Mutants of GST-CTD were prepared as described [11]. Brie£y,
GST-CTD was used as a template for PCR ampli¢cation with Pfu
DNA polymerase (Stratagene).
For mutations of the 14-3-3 binding motifs, we used the following
primers: S2576A-sense, 5P-CGTAAAGTTGCAGTGTCTGAATCA-
AA-3P, S2576A-antisense, 5P-TGATTCAGACACTGCAACATTTT-
TACGTAA-3P ; S2578A-sense, 5P-CGTAAAGTTGCAGTGGCCGA-
ATCA-3P, S2578A-antisense 5P-TGATTCGGCCACTGCAACTTTA-
CG-3P, S2580A-sense, 5P-CGTAAAGTTGCAGTGGCCGAAGCA-
AA-3P, S2580A-antisense, 5P-GAGAACATTTGCTTCGGCCACTG-
CAA-3P. For mutations of the PKA potential phosphorylation sites
we used the following primers: T2556A-sense, 5P-GTTTCAGTGG-
CCGAATCAAATGTTCTC-3P, T2556A-antisense, 5P-GAGAACAT-
TTGATTCGGACACTGAAAC-3P ; T2813A-sense, GTTTCAGTG-
TCTGAAGCAAATGTTCTC-3P, T2813A-antisense, 5P-GAGAAC-
ATTTGCTTCAGACACTGAAAC-3P. The sequences of the mutant
plasmids were con¢rmed using a BigDye Terminator sequence kit
(Applied Biosystems) and an ABI Prism 310 Genetic Analyzer (Ap-
plied Biosystems).
3. Results
3.1. Identi¢cation of 14-3-3 as a neuro¢bromin-associating
protein
To isolate proteins that physically associate with neuro¢-
bromin, rat brain cytosolic fraction was loaded on a GSH
column to which GST-CTD or GST was immobilized, and
the proteins bound to the columns were dissociated with
high salt elution bu¡er. As shown in Fig. 1A, ten proteins
with molecular masses between 175 and 10 kDa were repro-
ducibly obtained from the GST-CTD column, but none of
them was detected from the GST column. Analysis of the
protein band with a molecular mass of 31 kDa (p31) by
mass spectrometry revealed that six speci¢c [M]þ signals se-
lected in the tryptic peptide masses obtained from p31 (1189.6,
907.5, 669.3, 615.3, 1205.6, 1047.3) were well matched with
the calculated masses of tryptic fragments of rat 14-3-3 pro-
tein L/K/Q/R/j/N (protein kinase C inhibitor protein-1). Two
tryptic fragment masses with 1205.6 and 1315.6 were se-
quenced and identi¢ed as the 14-3-3 Q peptides of 217-226
(DSTLIMQLLR including an oxidation form of 219Met)
and 132-143 (YLAEVATGEK), respectively. Identi¢cation
of p31 as 14-3-3 protein was further con¢rmed with Western
blot analysis using anti-14-3-3 antibodies (Fig. 1B).
Biochemical interactions between 14-3-3 and endogenous
neuro¢bromin were tested by GST pull-down assay. Rat brain
lysates were incubated with GST or GST-14-3-3R and precipi-
tated with GSH beads. Endogenous neuro¢bromin signi¢-
cantly coprecipitated with GST-14-3-3R but not with GST
protein (Fig. 2). These results indicate that GST-14-3-3R in-
teracts with endogenous neuro¢bromin.
3.2. CTD of neuro¢bromin interacts with 14-3-3
To determine the 14-3-3 binding site of neuro¢bromin, var-
ious fragments of neuro¢bromin fused to GST were immobi-
lized on GSH beads, and then incubated with myc-tagged 14-
3-3R (myc-14-3-3R) overexpressed in COS-7 cells. This pull-
down assay (Fig. 3) showed that myc-14-3-3R strongly inter-
acts with GST-CTD, but not with other domains or GST
alone. We therefore concluded that 14-3-3R interacts only
with the CTD of neuro¢bromin.
3.3. Phosphorylation of neuro¢bromin enhances association
with 14-3-3
The 14-3-3 family proteins bind to various phosphorylated
proteins, such as Raf, Bcr, BAD, etc., via phosphorylated
serine residues [12]. Given that neuro¢bromin has been re-
ported to be constitutively phosphorylated on its serine/threo-
nine residues [9], we speculated that phosphorylation of neu-
ro¢bromin may a¡ect the interaction with 14-3-3. To examine
this possibility, we analyzed the interaction of myc-14-3-3R
with cellular endogenous neuro¢bromin. Myc-14-3-3R overex-
pressed in COS-7 cells was solubilized in the presence or ab-
sence of phosphatase inhibitors (10 mM NaF, 1 WM okadaic
acid). Lysates were immunoprecipitated with anti-myc or non-
immune mouse IgG, subjected to SDS^PAGE and immuno-
blotted with anti-GRP (D). Neuro¢bromin precipitation with
myc-14-3-3R in the presence of the phosphatase inhibitors
increased by up to four times compared with that in their
absence (Fig. 4). Reciprocally, immunoprecipitates with anti-
NF1-GRP (D) contained ¢ve times higher amounts of myc-
14-3-3R in the presence of the phosphatase inhibitors com-
pared with that in their absence. These results suggest that
phosphorylation of neuro¢bromin enhances interaction with
14-3-3.
Fig. 1. Identi¢cation of neuro¢bromin-associating proteins. A: Rat
brain proteins bound to the immobilized GST or GST-CTD are an-
alyzed by SDS^PAGE (12% PAGE gel, silver staining). The molecu-
lar weight markers are shown in kDa on the left and arrows indi-
cate the positions of the speci¢c binding proteins. The 31-kDa
protein indicated corresponds to 14-3-3. B: Rat brain proteins
bound to the immobilized GST or GST-CTD are immunoblotted
with anti-14-3-3 antibodies.
FEBS 28021 13-1-04
L. Feng et al./FEBS Letters 557 (2004) 275^282 277
3.4. Phosphorylation of neuro¢bromin by PKA activates its
binding to 14-3-3
It was previously reported that PKA is responsible for the
constitutive phosphorylation of neuro¢bromin [9]. Since the
experiment shown in Fig. 4 suggested that 14-3-3R binding to
neuro¢bromin potentially increases in a neuro¢bromin phos-
phorylation-dependent manner, we tested the possibility that
the phosphorylation of neuro¢bromin by PKA may involve
the enhancement of interaction between 14-3-3R and neuro-
¢bromin. We previously reported that PKA catalytic subunit
phosphorylates the immunoprecipitated native neuro¢bromin
as well as the GST-CTD fusion proteins. To assess whether
the PKA phosphorylation of GST-CTD fusion protein acti-
vates its binding to 14-3-3, we performed binding assay be-
tween 14-3-3R and GST-CTD in the presence or absence of
PKA catalytic fragments. As shown in Fig. 5, 14-3-3R bound
to GST-CTD fusion protein phosphorylated by PKA catalytic
fragments much more e⁄ciently than that unphosphorylated.
Furthermore, association of the endogenous 14-3-3R with
GST-CTD was inhibited by the addition of the inhibitor pro-
tein of cAMP-dependent protein kinase (PKI) (Fig. 5). These
results suggest that PKA phosphorylation of CTD is impor-
tant for regulation of the interaction between neuro¢bromin
and 14-3-3.
3.5. Binding of 14-3-3R negatively regulates the neuro¢bromin
GAP activity
Next, we examined whether the phosphorylation-mediated
binding of 14-3-3R regulates the GAP activity of neuro¢bro-
min. To measure the GAP activity of endogenous neuro¢bro-
min, we ¢rst established a pull-down assay system as de-
scribed in Section 2. Cell lysates were mixed with GST-H-
Ras-GTPQS or GST-H-Ras-GDPLS that was immobilized on
GSH beads, and the bound fractions on beads were identi¢ed
by immunoblotting using antibody against neuro¢bromin. As
shown in Fig. 6A, neuro¢bromin could bind to GST-H-Ras-
Fig. 2. GST pull-down assay showing that 14-3-3R interacts with endogenous neuro¢bromin in rat brain. Cell lysates of rat brain were incuba-
ted with GST or GST-14-3-3R immobilized onto GSH-agarose for 2 h at 4‡C with rocking. A: GST or GST-14-3-3R immobilized onto the aga-
rose beads is analyzed by immunoblotting with anti-GST. B: Neuro¢bromin bound on the beads is detected by immunoblotting with anti-neu-
ro¢bromin antibody [GRP (D)]. The arrowhead indicates the endogenous neuro¢bromin. The molecular weight markers are shown in kDa on
the left.
Fig. 3. Determination of 14-3-3R binding domain in neuro¢bromin. A: Schematic diagram of four neuro¢bromin domains. B: Myc-14-3-3R
was transfected into COS-7 cells, and the cell lysates were incubated with GST or GST-neuro¢bromin domain fusion proteins (GST-CSRD,
GRD, LRD, and CTD) immobilized onto GSH-agarose. Myc-14-3-3R bound on the beads was immunoblotted with anti-myc antibody. The ar-
row indicates the position of myc-14-3-3R.
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GTPQS in a dose-dependent manner, but not to GST-H-Ras-
GDPLS. To con¢rm that this binding activity corresponds to
that obtained from the original GAP assay, the same cell
lysates were subjected to the GAP ¢ltration assay using spe-
ci¢c NF1 antibody, as described [11]. As shown in Fig. 6B,
the NF1-GAP activity signi¢cantly increased in a cell extract
dose-dependent manner, and this was correlated to the results
obtained from the pull-down assay using GST-H-Ras-GTPQS
(Fig. 6A,B). These results indicate that the amount of neuro-
¢bromin bound to GST-H-Ras-GTPQS could re£ect the pool
of neuro¢bromin that is available to act on Ras, and is there-
fore an indirect measurement of cellular NF1-GAP activity, as
suggested by several GAP studies reported elsewhere [13^15].
By using this system, we found that neuro¢bromin GAP is
higher in PC12 cells than that in PC12 14-3-3R cells, although
the total amount of neuro¢bromin in the lysates is equal in
both cells (Fig. 6C). This was also con¢rmed by the ¢ltration
GAP activity assay (Fig. 6D). These results suggest that 14-3-
3 could negatively regulate neuro¢bromin function, perhaps
by a¡ecting its ability to interact with Ras-GTP.
To further verify whether the PKA phosphorylation of neu-
ro¢bromin enhances 14-3-3R binding to neuro¢bromin and
decreases the GAP activity of neuro¢bromin in living cells,
PC12 14-3-3R cells were treated with forskolin, an activator of
PKA, and its e¡ects on the 14-3-3 interaction and GAP ac-
tivity in vivo analyzed. Forskolin treatment enhanced the in-
teraction of the endogenous neuro¢bromin with 14-3-3R by
320U 5.1%, and suppressed the ability of neuro¢bromin to
bind Ras-GTP by 63.7U 5.4% compared to the control treat-
ment (Fig. 6E,F). These results strongly suggest that neuro-
¢bromin GAP activity is regulated via PKA phosphorylation
and 14-3-3 binding on CTD of neuro¢bromin.
3.6. Multiple substitutions of the potential phosphorylation sites
for 14-3-3 binding on CTD signi¢cantly a¡ects the
interaction of 14-3-3 with neuro¢bromin
To ¢nd out the phosphorylated sites of CTD a¡ecting the
binding between 14-3-3 and neuro¢bromin, several CTD mu-
tant proteins were prepared whose putative phosphorylation
sites of PKA or 14-3-3 binding motif (2576 Ser, 2578 Ser, 2580
Ser, 2556 Thr, and 2813 Ser) were mutated to Ala (point,
double, triple, and quintuple mutations) (Fig. 7), and tested
for their binding abilities. As shown in Fig. 7, none of the
point/double/triple mutations (lanes 1^8) a¡ected the 14-3-3R
binding with GST-CTD. However, only the quintuple muta-
tions on CTD signi¢cantly a¡ected the binding activity with
14-3-3 protein (Fig. 7, lanes 9 and 10). These results indicate
that a multiple cluster of phosphorylation on CTD (2576 Ser,
2578 Ser, 2580 Ser, 2554 Thr, and 2813 Ser) is necessary for
the binding of 14-3-3 and neuro¢bromin.
Fig. 4. E¡ects of phosphorylation of neuro¢bromin on the interaction with 14-3-3R. COS-7 cells transfected with or without myc-14-3-3R were
lysed with lysis bu¡er A in the presence or absence of phosphatase inhibitors (phosphatase inhibitor (PI): 10 mM NaF, 1 WM okadaic acid).
Cell extracts are either immunoprecipitated with anti-myc antibody or anti-neuro¢bromin [GRP (D)], resolved by SDS^PAGE, and immuno-
blotted with anti-neuro¢bromin [GRP (D)] or anti-myc antibody, respectively. The arrows indicate the positions of endogenous neuro¢bromin
(upper panel) and transfected myc-14-3-3R (lower panel). Note that interaction between myc-14-3-3R and neuro¢bromin was enhanced by the
presence of phosphatase inhibitors (**). Similar ¢ndings were observed in ¢ve independent experiments.
Fig. 5. In vitro phosphorylation of GST-CTD fusion protein by
PKA catalytic subunit activates its binding to 14-3-3R. GST-CTD
fusion protein (100 Wg) was incubated with GSH-agarose for 2 h at
4‡C. The immobilized GST-CTD was then incubated with or with-
out 30 U PKA (Sigma) in a total volume of 100 Wl kinase assay
bu¡er at 37‡C for 30 min. The treated GST-CTD protein was
mixed with cell lysates of PC12 14-3-3R in the presence or absence
of 2 WM PKI[6^22] amide (Sigma). The amount of myc-14-3-3R
binding to GST-CTD fusion protein was detected by immunoblot-
ting using anti-myc antibody. Similar ¢ndings were observed in ¢ve
independent experiments.
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4. Discussion
Neuro¢bromin, with a predicted size of 2818 amino acids,
holds a central GRD of 360 amino acids. Besides GRD, the
NF1 gene product has no clearly de¢ned functional domains
[16]. Given that most C-terminal mutations result in produc-
tion of the C-terminally truncated form of neuro¢bromin, it
can be speculated that the C-terminus of NF1 is crucial for
modulating functions of neuro¢bromin. Here, we identi¢ed
that 14-3-3 interacts with the CTD of neuro¢bromin in vitro
and in vivo, and negatively regulates the ability of neuro¢bro-
min to interact with Ras-GTP, consequently a¡ecting its GAP
activity.
We previously found that PKA is responsible for the con-
stitutive phosphorylation of neuro¢bromin [8]. Three lines of
evidence obtained in this study suggest that the PKA-depen-
dent phosphorylation of neuro¢bromin allows binding of 14-
3-3, which consequently inhibits the GAP activity of neuro-
¢bromin. First, the phosphorylation of GST-CTD by PKA
activated its binding to 14-3-3R and this interaction is abol-
ished by PKI treatment. Second, the GAP activity of neuro-
¢bromin was lower in 14-3-3R-overexpressed PC12 cells than
in parental PC12 cells. Third, treatment with forskolin, an
activator of adenylate cyclase, enhanced the interaction be-
tween endogenous neuro¢bromin and 14-3-3R, and sup-
pressed the binding activity of neuro¢bromin to Ras-GTP.
We believe that this is the ¢rst evidence that GAP activity is
regulated by PKA phosphorylation and followed by 14-3-3
binding.
The 14-3-3 proteins, in many but not all cases, bind to
phosphorylated form proteins. Phosphoserine binding motifs
for 14-3-3 proteins like RSXpSXP and RXXpSXP have been
identi¢ed by Rittinger et al. using oriented phosphopeptide
libraries [14]. Additionally, a novel 14-3-3 binding motif dis-
playing RX12SX23S has also been identi¢ed in Cbl protein
6
Fig. 6. 14-3-3R and forskolin negatively regulate NF1-GAP activity.
A: GAP activity assay of neuro¢bromin in PC12 cells by the GST-
Ras pull-down method. PC12 cells were lysed with bu¡er A, and in-
dicated amounts of the cell lysates were applied to the beads immo-
bilized with GST-Ras-GTPQS or GST-Ras-GDPLS and the bound
neuro¢bromin on the beads was separated by the SDS^PAGE and
detected by immunoblotting using anti-GRP (D) as described in
Section 2. A representative result is shown in the left panel, and the
averaged intensities of each band in ¢ve independent experiments
are plotted on the graph (right panel). B: GAP activity assay of
neuro¢bromin in PC12 cells by the ¢ltration assay method [11]. The
indicated amounts of cell lysates were incubated with GST-Ras-
[Q -32P]GTP in the presence of NF1-GAP antibody or preimmune
IgG for 2 h on ice, and passed through a ¢lter membrane. After
washing, the radioactivity of the ¢lter was counted. The total GAP
activities were obtained from the radioactivity di¡erences between
the total Ras-[Q -32P]GTP radioactivity and the sample radioactivity
that hydrolyzed after the GAP reaction. The speci¢c NF1-GAP ac-
tivity was obtained from the radioactivity di¡erence between the
sample radioactivity after the reaction with and without anti NF1-
GAP IgG. The activity of the other GAP activity was obtained
from the subtraction of the NF1-GAP activity from the total GAP
activity. C: Comparison of the GAP activities of neuro¢bromin be-
tween PC12 cells and PC12 14-3-3R cells by the GAP pull-down as-
say method using GST-Ras-GTPQS and GST-Ras-GDPLS. D: Com-
parison of the GAP activities of neuro¢bromin between PC12 cells
and PC12 14-3-3R cells by the GAP ¢ltration assay method using
GST-Ras-[Q -32P]GTP. E: Forskolin enhances the neuro¢bromin as-
sociation with 14-3-3R but decreases the neuro¢bromin binding ac-
tivity to GST-Ras-GTPQS. PC12-14-3-3R cells were treated with or
without 50 WM forskolin for 20 min at 37‡C. Cell extracts were im-
munoprecipitated with anti-myc antibody, and the precipitates were
immunoblotted with anti-neuro¢bromin antibody (two lanes in the
middle). For the GST-Ras-GTPQS pull-down assay, the same ex-
tracts were incubated with GST-Ras-GTPQS and immunoblotted
with anti-neuro¢bromin antibody (two lanes on the right). The total
cellular lysates were applied to the immunoblotting using anti-neu-
ro¢bromin and also used for the loading controls (two lanes on the
left). The ¢gure shows representative data from ¢ve separate identi-
cal experiments. F: Relative intensities of the results shown in E
were quantitated and are demonstrated as bar graphs. Data repre-
sent meansUS.D. values from ¢ve experiments performed in dupli-
cate.
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[17]. Neuro¢bromin is constitutively phosphorylated and
the speci¢c phosphorylation sites were determined in its
CSRD and CTD. Since one of the 14-3-3 binding motifs
(RX12SX23S) is present on the C-terminus of neuro¢bromin
(2573/2580 RKVSVSES), we tested the binding of 14-3-3R to
GST-CTD having substitution of three serine residues (2576
Ser, 2578 Ser, 2580 Ser) to alanine. However, those mutant
forms GST-CTD interacted with 14-3-3R in a similar manner
as the wild-type GST-CTD. The GST-CTD also contains two
potential PKA recognition sites (2556 Thr, 2813 Ser), but
neither the threonine nor the serine mutation form could af-
fect the 14-3-3 association with it. However, surprisingly,
when all of the mutations (Ser2578Ala, Ser2579Ala, Ser2581-
Ala, Thr2554Ala, and Ser2813Ala) were assembled on the
CTD, the interaction with 14-3-3 was almost abolished. These
results indicate that phosphorylation on all of the putative
PKA phosphorylation sites in addition to the 14-3-3 binding
motif on CTD is necessary for the association between 14-3-3
and neuro¢bromin, and this phosphorylation may regulate
the neuro¢bromin function via the 14-3-3 binding. More pre-
cise study will be needed to clarify the mechanism of this
interaction between 14-3-3 and neuro¢bromin in detail.
The interaction of 14-3-3 protein is known to modulate
target proteins. These functions can be assembled into ¢ve
categories: (1) alteration of the ability of the target protein
to interact with other partners; (2) relocalization of the cyto-
plasmic/nuclear partition of the protein partner; (3) protec-
tion of the target protein from proteolysis and/or dephosphor-
ylation; (4) serving as a phosphorylation-dependent adapter/
sca¡old to bridge two targets; and (5) inhibition or enhance-
ment of the intrinsic catalytic activity of the target protein
[12]. Various enzymes such as serotonin N-acetyltransferase,
and the ASK-1 kinase activity, have been found to have their
activities modi¢ed by interaction with 14-3-3 protein [12].
However, no reports have described the modi¢cation of
NF1 function by 14-3-3. Our present data propose a novel
function wherein 14-3-3R interacts with neuro¢bromin and
negatively regulates its function.
In Drosophila, the mechanism of NF1-dependent activation
of the Rut-adenylyl cyclase pathway is essential for mediating
learning and memory [18,19]. In a mouse model of NF1, the
learning de¢cits may be caused by excessive Ras activity,
which leads to impairments in long-term potentiation caused
by increased GABA-mediated inhibition [16]. Manifestation
in NF1 patients is in learning and memory disorders; and it
seems likely that 14-3-3 might be related to the NF1-related
learning and memory disorders because it decreases the func-
tion of neuro¢bromin. However, further studies will be
needed to prove this hypothesis.
We recently reported that NF1-GAP activity is increased in
PC12 cells when neuron-like di¡erentiation is induced by
nerve growth factor (NGF) treatment [11]. This NF1-GAP
increase, which is required for neurite extension, was caused
by the alternative splicing changes in the NF1-GAP domain;
and we suggested that NGF stimulation induces the splicing
of NF1-GRD type I isoform which possesses higher GAP
activity than the type II isoform, and regulates the cellular
GAP activity via a Ras phosphoinositide 3P-kinase signal in-
duction [11]. In the present study, we have shown that NF1
function is regulated not only by the splicing alteration in the
GAP domain but also by phosphorylation of the C-terminal
region followed by interaction with 14-3-3. Given that we
previously demonstrated that neuro¢bromin is constitutively
phosphorylated by PKA [9], GAP activity might be lower in
normal growing cells. It can be speculated that external or
internal signals which inhibit PKA activity may prevent 14-
3-3 from interacting with neuro¢bromin, resulting in activa-
tion of NF1 function, which leads to suppression of the Ras-
related signal pathways inducing cell cycle arrest. We believe
this is the ¢rst report to support that PKA phosphorylation
regulates neuro¢bromin function via 14-3-3 binding. Further
information based on this study should give new insights into
NF1-related pathogenesis.
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